



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/577,395	04/27/2007	Ronald W. Wood	176/61672(1246)	1398

26774 7590 02/03/2010
NIXON PEABODY LLP - PATENT GROUP
1100 CLINTON SQUARE
ROCHESTER, NY 14604

EXAMINER

QIAN, CELINE X

ART UNIT	PAPER NUMBER
----------	--------------

1636

MAIL DATE	DELIVERY MODE
-----------	---------------

02/03/2010

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary	Application No. 10/577,395	Applicant(s) WOOD ET AL.	
	Examiner CELINE X. QIAN	Art Unit 1636	

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-47 is/are pending in the application.
- 4a) Of the above claim(s) 18-47 is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☒ Claim(s) 1-17 is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☐ Claim(s) ____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☒ The drawing(s) filed on 07 April 2006 is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
 2. ☐ Certified copies of the priority documents have been received in Application No. ____.
 3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- | | |
|--|---|
| 1) <input checked="" type="checkbox"/> Notice of References Cited (PTO-892) | 4) <input type="checkbox"/> Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____. |
| 2) <input type="checkbox"/> Notice of Draftperson's Patent Drawing Review (PTO-948) | 5) <input type="checkbox"/> Notice of Informal Patent Application |
| 3) <input checked="" type="checkbox"/> Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date <u>0406.0209</u> . | 6) <input type="checkbox"/> Other: ____. |

Art Unit: 1636

DETAILED ACTION

Claims 1-47 are pending in the application.

Election/Restrictions

Applicant's election without traverse of Group I in the reply filed on 1/8/10 is acknowledged.

Accordingly, claims 18-47 are withdrawn from consideration for being directed to non-elected subject matter. Claims 1-17 are currently under examination.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on 4/27/06 and 2/10/09 have been considered by the examiner.

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1-17 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the enablement requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to enable one skilled in the art to which it pertains, or with which it is most nearly connected, to make and/or use the invention.

There are many factors to be considered when determining whether there is sufficient evidence to support a determination that a disclosure does not satisfy the enablement requirement and whether any necessary experimentation is "undue." These factors include, but are not limited to: (a) the nature of the invention; (b) the breadth of the claims; (c) the state of the prior

Art Unit: 1636

art; (d) the amount of direction provided by the inventor; (e) the existence of working examples; (f) the relative skill of those in the art; (g) whether the quantity of experimentation needed to make or use the invention based on the content of the disclosure is "undue"; and (h) the level of predictability in the art (MPEP 2164.01 (a)).

The nature of the invention:

The claimed invention is drawn to a method of diagnosing a pelvic pain disorder comprising measuring a level of CGRP or PACAP, or both, in the patient sample in relation to a standard level in a normal asymptomatic population, wherein the measured level of CGRP or PACAP, or both is elevated indicates the diagnosis of a pelvic pain disorder. The claimed invention is also drawn to a method of determining predisposition of an individual to conditions associated with pelvic pain disorder comprising measuring a level of CGRP or PACAP, or both, in the patient sample in relation to a standard level in a normal asymptomatic population, wherein the measured level of CGRP or PACAP, or both is elevated indicates the individual is predisposed to conditions associated with a pelvic pain disorder.

The breadth of the claim:

The breadth of the claim is very broad. The independent claims are drawn to a method of either diagnosing or predicting any type of pelvic pain disorder based on the level of CGRP, PACAP alone or in combination, present in any tissue or body fluids. The pelvic pain disorder encompasses any disorder of known or unknown cause which has the symptom of pelvic pain, including interstitial cystitis, Crohn's disease, ulcerative colitis, irritable bowel syndrome...etc. As such, the breadth of the claimed method is very broad.

The teaching of the specification and the presence of working examples:

Art Unit: 1636

The specification discloses a method of diagnosing a pelvic pain disorder comprising measuring a level of CGRP or PACAP, or both, in the patient sample in relation to a standard level in a normal asymptomatic population, wherein the measured level of CGRP or PACAP, or both is elevated indicates the diagnosis of a pelvic pain disorder. The specification also discloses a method of determining predisposition of an individual to conditions associated with pelvic pain disorder comprising measuring a level of CGRP or PACAP, or both, in the patient sample in relation to a standard level in a normal asymptomatic population, wherein the measured level of CGRP or PACAP, or both is elevated indicates the individual is predisposed to conditions associated with a pelvic pain disorder. However, aside from the prophetic teaching that CGRP or PACAP, alone or in combination may be used to predicting the predisposition and diagnosing pelvic pain associated disorder, the specification fails provide any evidence that such method would actually work in human or in any animal model of such disease. In Example 1 and 2, the specification discloses that 15 patient suffer from one type of pelvic pain associated disorder, interstitial cystitis (IC), has elevated CGRP peptide in their urine compared to the 9 control individual who do not have this disease. The specification discloses that 75% of IC patients have CGRP levels greater than 1.92 ng/mg creatinine, and that 75% of control subjects have level less than 1.82 ng/mg creatinine. The specification, however, fails to even mention whether the level of PACAP, in urine or other tissue, body fluid, is related to any type of disorder that is associated with pelvic pain. Based on the teaching of the specification, whether diagnosing or determining predisposition of any disorder associated with pelvic pain based on PACAP is unpredictable because the nexus between the peptide and any pelvic pain disorder is missing. Further, whether diagnosing or determining predisposition of any disorder associated

Art Unit: 1636

with pelvic pain based on CGRP is also unpredictable because the small sample size and small difference between patient and standard control of a single experiment does not establish how the determination of pelvic pain disorder may be diagnosed or predicted. According to the data in Figure 2, the range of the level of CGRP of patients overlaps with the range of the control even without considering the standard deviation. In other words, if the level of CGRP present in a urine sample is 1.90 ng/mg creatinine, does this person have pelvic pain disorder? Furthermore, the specification does not disclose whether the elevated level of CGRP is resulted from IC or preceded from the development of IC. As such, it is unclear how to determine the predisposition of IC based on such finding. The specification also fails to disclose whether other types of pelvic pain disorder, for example, Crohn's disease, ulcerative colitis, which different mechanism from IC, also has elevated CGRP in urine. As such, whether any type of pelvic pain disorder may be diagnosed or predicted based on CGRP is unpredictable.

The state of prior art and the level of prediction in the prior art:

The state of prior art at the time of filing is silent on whether measuring the level of CGRP and PACAP alone or in combination may be used to determine the predisposition and diagnosing any pelvic pain disorder. Vizzard (The Journal of Comparative Neurology, 2000. Vol. 420, pages 335-348) teach that PACAP is up-regulated in spinal segments and DRG, and the percent of bladder afferent cells expressing PACAP also increased in a rat model when chronic cystitis is induced by cyclophosphamide (see page 339-344). However, Vizzard does not teach whether the elevated level of PACAP may be use to diagnose pelvic pain disorder in said animal model. Further, it appears that the elevation of PACAP occurs following cyclophosphamide treatment. As such, whether this elevation may be used to determine a

Art Unit: 1636

predisposition of a pelvic pain disorder is unpredictable. Kreder et al. (IDS) disclose that CGRP level is elevated in the urine sample of IC patients following chlorpactin treatment. Kreder et al. disclose that IC patients has very low level of CGRP in urine sample pre and post-hydrodistention, the level only elevated following chlorpactin treatment. Kreder et al. speculate that chlorpactin works by increased releasing of CGRP from nociceptive nerve terminals. In view of this teaching, it appears that CGRP level in urine is not related to the IC itself, rather, the treatment of chlorpactin may be responsible for such elevation. As such, whether the level of CGRP may be used to predict a predisposition or diagnose pelvic disorder is unpredictable.

In summary, neither the specification nor the prior art establishes a nexus between CGRP, PACAP alone or in combination and pelvic disorder diagnosis or disposition. In view of lack of teaching from the specification and prior art, the skilled artisan would have to engage in undue experimentation to practice the method as claimed. Therefore, the claimed invention is not enabled by the instant specification.

No claims are allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to CELINE X. QIAN whose telephone number is (571)272-0777. The examiner can normally be reached on 10-6:30 M-F.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 1636

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Celine X Qian /
Primary Examiner, Art Unit 1636